The value of randomized clinical trials in radiation oncology clinical practice

May 29, 2013

CHAPEL HILL, N.C. - Cancer patients, physicians and insurers want to be sure that whatever therapy is recommended and provided to patients is based on evidence, preferably results from randomized clinical trials. But are there enough clinical trials data to provide this level of confidence?

A University of North Carolina School of Medicine study says not necessarily. Radiation oncologists evaluated how often patients were seen in their clinic with medical decisions to be made that were not specifically addressed by randomized controlled trials.

They determined that in a group of 393 patients who were being treated with curative intent with multiple tumor types, 47 percent of all medical decisions were made without available or applicable randomized evidence to inform clinical decision making.

The study is the only known published study to evaluate the availability of evidence in a routine clinical setting for any medical specialty. It was published in the June issue of the journal Cancer.

"Randomized controlled trials are the lynchpin of clinical care, but the results are often not applicable to an individual patient, so all care cannot be provided entirely on the basis of those trials. We're not speaking against clinical trials. We're just pointing out their limitations in daily cancer care," said Joel Tepper, MD, senior author. Dr. Tepper is Hector McLean Distinguished Professor of Cancer Research, professor of radiation oncology and a member of UNC Lineberger Comprehensive Cancer Center.

Dr. Tepper said the study draws attention to several issues. "The potential negative consequences of evidence-based coverage policies may impede necessary and appropriate patient care. If the standard of adequate evidence in the form of randomized clinical trials are often not generalizable to patients, the appropriateness of using randomized data as the basis for coverage of every patient comes into question." Observational studies, trials conducted without randomization, are an option to inform decisions when randomized trials are not available.

"Additionally, we hope that our study results suggest that well-designed observational studies and alternative clinical trial designs may play a central role in the continued development of evidence for medical decision making in select patient groups," said Dr. Tepper. It also emphasizes the need for a robust clinical trial system that will generate more randomized trial data to inform clinical decision making.

"Our results also emphasize the importance of clinical judgment and experience in what we recommend to our patients. Tumor boards, when a patient's case is evaluated by a number of medical specialties, can also be extremely useful," he said.

The UNC group reviewed medical records of 393 patients evaluated for treatment in the UNC radiation oncology clinic. Patients with cancer of the breast (30 percent), head and neck (18 percent), and genitourinary (14 percent) were the most common tumor types included in the study. Patient medical decisions were classified as those with (Group 1) or without (Group 2) randomized clinical trials data. Group 1 was further divided into three groups based on the extent of fulfilling eligibility criteria for each randomized clinical trial: 1a) fulfilling all eligibility criteria; 1b) not fulfilling at least one minor eligibility criteria; and 1c) not fulfilling at least one major eligibility criteria. The availability of high level evidence varied by tumor type.
-end-
Other study authors are Smith Apisarnthanarax, MD, and Samuel Swisher-McClure, MD, University of Pennsylvania Abramson Cancer Center in Philadelphia; Randall Kimple, MD, PhD, University of Wisconsin in Madison; Stephen Harris, MD, Radiation Oncology Associates, Manchester, New Hampshire; David Morris, MD, St. Louis CyberKnife Center in St. Louis, Missouri and Wing Chiu, PhD, UNC.

University of North Carolina Health Care

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.